Centiva Capital’s bluebird bio BLUE Stock Holding History

Centiva Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,005	Closed	-$166K	–	1500
2022 Q2	$166K	Buy	+2,005	New	+$155K	﹤0.01%	1328

Other funds holding BLUE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Centiva Capital's BLUE Position: Q3 2022 in Review

Centiva Capital sold out of bluebird bio (BLUE) in Q3 2022, closing a stake of 2,005 shares — an estimated $166K sold.

Centiva Capital first reported a position in BLUE in Q2 2022 and held it in 1 quarter. The position peaked at $166K in Q2 2022. 162 funds tracked by Wall St. Rank hold BLUE as of Q3 2022.

Centiva Capital reported no remaining bluebird bio position as of Q3 2022 after selling out during the quarter.
Centiva Capital sold 2,005 bluebird bio shares in Q3 2022, an estimated $166K.
Centiva Capital first reported a position in bluebird bio in Q2 2022 and held it in 1 quarter.
Centiva Capital's bluebird bio position peaked at $166K in Q2 2022.
162 funds tracked by Wall St. Rank held bluebird bio as of Q3 2022.

Based on Centiva Capital's 13F filing for Q3 2022, filed 14 Nov 2022.